Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL: Anemia Management in ESRD with Secondary Hyperparathyroidism
NCT02273570Unknown
- Sponsor
- Azienda Ospedaliera Ospedale Sant'Anna di Como
- Start
- Mar 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cinacalcet in secondary hyperparathyroidism (SHPT) and anemia (2 arms), sponsored by Azienda Ospedaliera Ospedale Sant'Anna di Como. Primary endpoint: percent reduction in weekly ESA consumption at 12 months. Status: unknown.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)anemia
Beyond the preview
Go deeper on NCT02273570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273570.